Health Care Resource Use and Cost Burden of Chronic Kidney Disease in Patients With Chronic Liver Disease: A Real‐World Claims Analysis. Issue 10 (2nd August 2020)

• Record Type: Journal Article
• Authors: Rustgi, Vinod K.; Li, You; John, Tina; Catalano, Carolyn; Elsaid, Mohamed I.
• Is Part Of: Hepatology communications. Volume 4:Issue 10(2020)
• Page Start: 1404
• Page End: 1418
• Publication Date: 2020-08-02
• Subjects: Hepatology -- Periodicals; Liver -- Diseases -- Periodicals; Liver Diseases; Gastroenterology; Periodicals; Fulltext; Internet Resources; Periodicals; 616.36
• DOI: 10.1002/hep4.1573
• Languages: English
• ISSNs: 2471-254X

Abstract

Abstract : Chronic Liver Disease (CLD) is associated with an increased risk of chronic kidney disease (CKD). However, the health care burden of CKD in the CLD spectrum is unknown. We aimed to evaluate the health care use and cost burdens associated with CKD in patients with CLD in the United States by using real‐world claims data. We analyzed data from the Truven Health MarketScan Commercial Claims database from 2010 to 2015. A total of 19, 664 patients with CLD with or without comorbid CKD were identified using International Classification of Diseases, Ninth Revision, codes and matched 1:1 by sociodemographic characteristics and comorbidities using propensity scores. Total and service‐specific unadjusted and adjusted health care parameters were analyzed for the 12 months following an index date selected at random to capture whole disease burdens. In CLD, comorbid CKD was associated with a higher annual number of claims per person (CKD vs. no CKD, 69 vs. 55) and higher total annual median health care costs (CKD vs. no CKD, $21, 397 vs. $16, 995). A subanalysis stratified by CKD category showed that health care use and cost burden in CLD increased with disease stage, with a peak 12‐month median cost difference of $77, 859 in patients on dialysis. The adjusted per person annual health care cost was higher for CKD cases compared to controls ($35, 793 vs. $24, 048, respectively; P < 0.0001). Stratified by the type of CLD, the highest between‐group adjusted cost differences were for cirrhosis, viral hepatitis, hemochromatosis, and nonalcoholic fatty liver disease. Conclusion: CKD is a cost multiplier in CLD. The CKD health care burden in liver disease differs by the type of CLD. Improved CKD screening and proactive treatment interventions for at‐risk patients can limit the excess burden associated with CKD in patients with CLD. Abstract :